Is UNH Stock Set For Another 12% Rally? Analyst Says Medical Cost Trends, Supportive Data Points Leading Toward Favorable Q2

• Fischbeck noted that incoming data points made it difficult to believe that the strong first quarter was purely a ‘function of weak flu and storms.’ 
• Morgan Stanley analyst Erin Wright raised UnitedHealth's price target to $453 from $395 and maintained an ‘Overweight’ rating.
• Truist noted that first-quarter medical cost trends were favorable relative to consensus expectations, with forward guidance maintaining an upward bias.

Shares of UnitedHealth Group Inc. (UNH) surged over 5% on Thursday after multiple Wall Street firms raised their outlooks on the healthcare insurance giant, citing improving medical cost trends and a favorable second-quarter earnings setup.

Morgan Stanley Says UNH 'Grinding Higher' On Softer Utilization, AI Tailwinds 

Morgan Stanley analyst Erin Wright raised UnitedHealth's price target to $453 from $395 and maintained an ‘Overweight’ rating, according to TheFly. The latest price target implies over 12% upside potential from current levels.

Wright noted that managed care stocks have been ‘grinding higher’ on emerging signs of softer utilization trends. The analyst also explored potential AI tailwinds for managed care organizations across revenue and cost levers and estimated that AI-driven efficiencies could deliver roughly 45% average earnings-per-share upside for managed care organizations as efficiency scales.

BofA Sees Improving Medical Cost Trends 

BofA analyst Kevin Fischbeck upgraded UnitedHealth's rating to ‘Buy’ from ‘Neutral’ and raised the price target to $450 from $420. 

Fischbeck also noted that incoming data points made it difficult to believe that the strong first quarter was purely a ‘function of weak flu and storms.’ The analyst sees that improving medical cost trends and supportive near-term data points are setting up a favorable Q2 earnings setup.

He also said that UnitedHealth should lead a broader rally of managed care organizations if utilization trends continue to moderate.

Earlier this week, Truist also raised its price target on UnitedHealth to $440 from $395 and kept a ‘Buy’ rating on the stock, as a broader take on managed healthcare firms.    

The firm expects meaningful embedded earnings potential tied to ongoing margin recovery across the government businesses, and also expects continued solid trends in the Commercial business. Truist noted that Q1 medical cost trends landed favorably versus consensus expectations, with forward guidance maintaining an upward bias.

According to Koyfin data, 22 of 28 analysts rate the stock ‘Buy,’ or higher, five recommend ‘Hold’, and one has a ‘Sell’ rating.

On June 3, the board authorized a dividend of $2.32 per share to be paid on June 23, 2026. The company reported first-quarter revenue of $111.7 billion, beating analysts' expectations, while adjusted earnings came in at $7.23 per share, surpassing Wall Street's $6.61 estimate.

What Retail Thinks Of UNH

On Stocktwits, retail sentiment surrounding the stock has improved to ‘neutral’ from ‘bearish’ while message volumes increased to ‘normal’ from ‘low’ in the past 24 hours. 

One user on Stocktwits said the dividend raise is instilling some confidence.

UNH stock has gained more than 18% year-to-date.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: Why Did ROLR Stock Surge 20% Today?